Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
| ▸ | FLT4 | P35916 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30550465 | 1.00 | EGFR (0.42) | EGFRNFE2L2XDHMEN1KMT2A | |
| SCHEMBL12261421 | 0.89 | KDM4E (0.45) | EGFRNFE2L2XDHMEN1KMT2A | |
| SCHEMBL29385499 | 0.89 | KDM4E (0.45) | EGFRNFE2L2XDHMEN1KMT2A | |
| SCHEMBL29181804 | 0.85 | MAOA (0.39) | MAOAKDM4EBRD4ALDH1A1MAOB | |
| SCHEMBL11030544 | 0.84 | BRD4 (0.46) | EGFRNFE2L2MEN1KMT2AMAOA | |
| SCHEMBL228911 | 0.83 | MEN1 (0.53) | EGFRNFE2L2MEN1KMT2AMAOA | |
| SCHEMBL21098689 | 0.81 | EGFR (0.41) | EGFRNFE2L2MEN1KMT2AMAOA | |
| SCHEMBL24755482 | 0.81 | EGFR (0.41) | EGFRNFE2L2XDHMEN1KMT2A | |
| SCHEMBL7340707 | 0.81 | KDM4E (0.54) | EGFRKDM4EALDH1A1KITPDGFRA | |
| SCHEMBL30232207 | 0.81 | EGFR (0.41) | EGFRNFE2L2MEN1KMT2AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098049-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-12528828-B2 | Substituted pyrido[4,3-d]pyrimidines as KRAS modulators | ALTEROME THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250346610-A1 | SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS | ALTEROME THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| WO-2025064542-A1 | KRAS MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| WO-2024178304-A1 | KRAS MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2024-08-29 | — | — | WO | disclosed |
| US-20230357233-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-11-09 | — | — | US | disclosed |
| CN-116514771-A | Carboxylic acid compound, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2023-08-01 | — | — | CN | disclosed |
| WO-2023141570-A2 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | ARVINAS OPERATIONS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023141570-A2 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | ARVINAS OPERATIONS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023104018-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUND AS KRAS G12D INHIBITOR | 苏州浦合医药科技有限公司 | 2023-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346610-A1 | SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS | KRAS, NRAS, HRAS | EGFR 301/4885NFE2L2 2048/4885XDH 2253/4885 |
| US-12528828-B2 | Substituted pyrido[4,3-d]pyrimidines as KRAS modulators | KRAS, NRAS, HRAS | EGFR 50/4885NFE2L2 2024/4885XDH 839/4885 |
| US-20260098049-A1 | KRAS MODULATING COMPOUNDS | KRAS, NRAS, HRAS | EGFR 18/4885NFE2L2 489/4885XDH 4843/4885 |
| US-20230357233-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | KRAS, NRAS, HRAS | EGFR 64/4885NFE2L2 1011/4885XDH 3383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.